Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · SMSPHARMA

SMS PHARMACE

HealthcarePharmaceuticals & Biotechnology₹4472 cr market cap
₹481.35 ▲ +0.95% today As of 19 Nov 2026
52-week low ₹271.5552-week high ₹525.50

-9.3% from the 52-week high · +75.6% above the low

SMS Pharmaceuticals Ltd. is a holding company, which engages in the research, development and marketing of active pharmaceutical ingredients. The company is headquartered in Hyderabad, Telangana and currently employs 1,095 full-time employees. The company went IPO on 2007-02-25. The firm is engaged in the business of manufacturing of active pharma ingredients and their intermediates. Its product categories include anti-ulcer, anti-inflammatory, anti-migraine, ant-diabetic, anti-coagulant, anti-viral, anti-retroviral, anti-psychotic and others. The firm products include ranitidine, famotidine, pantoprazole sodium, itraconazole, lanoconazole, luliconazole, ibuprofen, Dex ibuprofen, fenoprofen calcium, sumatriptan, almotriptan, zolmitriptan, rizatriptan, Ele triptan, vildagliptin, sitagliptin, rosiglitazone, empagliflozin, dapagliflozin, tenofovir, dolutegravir, raltegravir, lamivudine, efavirenz, apixaban, rivaroxaban, levetiracetam, perampanel and lamotrigine. The firm has manufacturing facilities at Bachupally, Hyderabad, Telangana and also at Kandivalasa Village, Poosapatirega Mandal, Vijayanagaram District, Andhra Pradesh.

The short version. SMS PHARMACE reported revenue of ₹316 crore for Sep 2026, up 30.6% from a year earlier. Net profit was ₹40 crore (up 60.0% year on year). Return on equity was 13.0% in Mar 2026. Promoter holding was 68.07% in Sep 2026, up 3.40 points over 8 quarters.

1 · The price

How has the stock traded?

SMS PHARMACE trades 9.3% below its 52-week high and 75.6% above its 52-week low.

Change over period: —

1M+9.7%
3M+33.9%
6M+12.4%
1Y+67.5%

2 · The business

Is it growing?

Sales, year on year+30.6%

Sep 2026 revenue of ₹316 cr.

Profit, year on year+60.0%

Sep 2026 net profit of ₹40 cr.

Net margin12.6%

2.2 pts higher than a year earlier.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue316207238210242196248173
Net profit4021332325202018
Net margin %12.610.113.911.210.410.58.210.5
EPS (₹)4.262.233.522.512.72.192.292.16

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue887783709522520563412465
Net profit1026950-762633353
Net margin %11.58.87.0-1.412.011.17.911.5
EPS (₹)10.97.85.89-0.837.357.393.866.31

3 · The quality

How well does it turn capital into profit?

Return on equity was 13.0% in Mar 2026; debt to equity is 0.46.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %13.010.89.3-1.5
Return on capital %13.813.412.84.4
EBITDA margin %20.118.417.011.3
Net margin %11.48.87.0-1.3

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR19.3%9.6%
Profit CAGR—10.3%
Debt to equity0.46
Interest cover6.1x
Current ratio1.81
P/E ratio38.1

4 · The owners

Who holds it, and are they adding?

Promoter holding68.07%

Up 3.4 pts over 8 quarters.

Foreign institutions1.18%

Up 0.87 pts over 8 quarters.

Domestic institutions0.2%

Down 2.35 pts over 8 quarters.

Mutual fund schemes2

+0 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter64.6766.2668.0768.0768.0768.0768.0768.07+3.4
FII0.310.080.170.280.040.310.651.18+0.87
DII2.552.432.882.883.213.022.830.2-2.35
Public32.4731.2228.8928.7828.6928.628.4530.56-1.91

Mutual fund holdings · Oct 2026

2 schemes hold this stock

2 the month before.

  • Motilal Oswal BSE Healthcare ETF0.09% of NAV
  • Bandhan BSE Healthcare Index Fund0.09% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for SMS PHARMACE are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about SMS PHARMACE

What is the SMS PHARMACE share price?

SMS PHARMACE (SMSPHARMA) last closed at ₹481.35, up 0.95% on the day. Its 52-week range is ₹271.55 to ₹525.50.

What is the market cap of SMS PHARMACE?

SMS PHARMACE has a market capitalisation of about ₹4,472 crore. Its price-to-earnings ratio is 38.1.

How are SMS PHARMACE's latest results?

SMS PHARMACE reported revenue of ₹316 crore for Sep 2026, up 30.6% from a year earlier. Net profit was ₹40 crore (up 60.0% year on year). Return on equity was 13.0% in Mar 2026. Promoter holding was 68.07% in Sep 2026, up 3.40 points over 8 quarters.

Who owns SMS PHARMACE?

As of Sep 2026, shareholding was: Promoter 68.07%, FII 1.18%, DII 0.2%, Public 30.56%.

How many mutual funds hold SMS PHARMACE?

2 mutual fund schemes held SMS PHARMACE in October 2026. That compares with 2 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 22 Sep 2025 · Final Dividend - Rs. 0.4
  • 23 Sep 2024 · Final Dividend - Rs. 0.4
  • 22 Sep 2023 · Final Dividend - Rs. 0.3
  • 22 Sep 2022 · Final Dividend - Rs. 0.3
  • 22 Sep 2021 · Final Dividend - Rs. 0.3
  • 26 Mar 2020 · Interim Dividend - Rs. 0.25

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.